Neurology Medical News about Multiple Sclerosis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
The Lancet Neurology, 10/16/09

Kappos L et al. – Effects on the rate of conversion to CDMS and the favourable long–term safety and tolerability profile support early initiation of treatment with interferon beta–1b, although a delay in treatment by up to 2 years did not affect long–term disability outcomes.

<< Previous
The Clinical Course of Advanced Dementia

Next >>
Antiphospholipid antibodies and risk of myocardial infarction and...